Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 4/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.31 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13000049 | 1.00 | SAT1 (0.39) | SAT1GABBR2GABBR1TSHRCYP3A4 | |
| SCHEMBL16533835 | 0.94 | PLA2G2C (0.37) | SAT1GABBR2GABBR1TSHRCYP3A4 | |
| SCHEMBL16815000 | 0.89 | SAT1 (0.45) | SAT1TSHRCYP3A4ALDH1A1 | |
| SCHEMBL16815001 | 0.89 | SAT1 (0.45) | SAT1TSHRCYP3A4ALDH1A1 | |
| SCHEMBL16814867 | 0.89 | SAT1 (0.45) | SAT1TSHRCYP3A4ALDH1A1 | |
| SCHEMBL16815008 | 0.89 | SAT1 (0.45) | SAT1TSHRCYP3A4ALDH1A1 | |
| SCHEMBL2606244 | 0.86 | — | — | |
| SCHEMBL10067773 | 0.82 | SAT1 (0.41) | SAT1TSHRCYP3A4ALDH1A1 | |
| SCHEMBL5032838 | 0.82 | LPAR3 (0.40) | GABBR2GABBR1TSHRCYP3A4ALDH1A1 | |
| SCHEMBL20746730 | 0.82 | LPAR3 (0.40) | GABBR2GABBR1TSHRCYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9574189-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2017-02-21 | — | — | US | disclosed |
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | RNGTT, DUT, EMG1 | SAT1 1501/4885GABBR2 3935/4885GABBR1 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.